These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17146106)

  • 1. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
    Roboz GJ; Giles FJ; Ritchie EK; Allen-Bard S; Curcio TJ; Wilkes MA; Park SL; Kantarjian HM; Faderl S; Ravandi F; Kelner MJ; Feldman EJ
    J Clin Oncol; 2007 Jan; 25(1):10-5. PubMed ID: 17146106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
    Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
    J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
    Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
    Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    de Bono JS; Stephenson J; Baker SD; Hidalgo M; Patnaik A; Hammond LA; Weiss G; Goetz A; Siu L; Simmons C; Jolivet J; Rowinsky EK
    J Clin Oncol; 2002 Jan; 20(1):96-109. PubMed ID: 11773159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
    J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
    Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM
    J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
    Lin CC; Beeram M; Rowinsky EK; Takimoto CH; Ng CM; Geyer CE; Denis LJ; De Bono JS; Hao D; Tolcher AW; Rha SY; Jolivet J; Patnaik A
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):167-75. PubMed ID: 19449006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Troxacitabine-based therapy of refractory leukemia.
    Giles FJ
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):261-6. PubMed ID: 12113049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
    Jimeno A; Messersmith WA; Lee CK; Ma WW; Laheru D; Donehower RC; Baker SD; Hidalgo M
    Ann Oncol; 2008 Feb; 19(2):374-9. PubMed ID: 18245131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
    Giles FJ; Garcia-Manero G; Cortes JE; Baker SD; Miller CB; O'Brien SM; Thomas DA; Andreeff M; Bivins C; Jolivet J; Kantarjian HM
    J Clin Oncol; 2002 Feb; 20(3):656-64. PubMed ID: 11821445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
    Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
    Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Troxacitabine activity in extramedullary myeloid leukemia.
    Alvarado Y; Kantarjian HM; Cortes JE; Apostolidou E; Bivins C; Giles FJ
    Hematology; 2002 Jun; 7(3):179-85. PubMed ID: 12243982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
    Giles F; Rizzieri D; Karp J; Vey N; Ravandi F; Faderl S; Khan KD; Verhoef G; Wijermans P; Advani A; Roboz G; Kantarjian H; Bilgrami SF; Ferrant A; Daenen SM; Karsten V; Cahill A; Albitar M; Mufti G; O'Brien S
    J Clin Oncol; 2007 Jan; 25(1):25-31. PubMed ID: 17146105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
    Schiller GJ; O'Brien SM; Pigneux A; Deangelo DJ; Vey N; Kell J; Solomon S; Stuart RK; Karsten V; Cahill AL; Albitar MX; Giles FJ
    J Clin Oncol; 2010 Feb; 28(5):815-21. PubMed ID: 20026800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
    Bélanger K; Moore M; Baker SD; Dionne J; Maclean M; Jolivet J; Siu L; Soulières D; Wainman N; Seymour L
    J Clin Oncol; 2002 May; 20(10):2567-74. PubMed ID: 12011137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
    Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
    Giles FJ; Kantarjian HM; Cortes JE; Garcia-Manero G; Verstovsek S; Faderl S; Thomas DA; Ferrajoli A; O'Brien S; Wathen JK; Xiao LC; Berry DA; Estey EH
    J Clin Oncol; 2003 May; 21(9):1722-7. PubMed ID: 12721247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
    Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
    J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.